Intellipharmaceutics International Inc. (IPCI) Given a $8.00 Price Target at Brean Capital
Intellipharmaceutics International Inc. (NASDAQ:IPCI) has been given a $8.00 target price by equities researchers at Brean Capital in a research report issued to clients and investors on Monday. The brokerage presently has a a “buy” rating on the stock. Brean Capital’s price target would indicate a potential upside of 179.72% from the company’s previous close.
Several other brokerages have also recently issued reports on IPCI. Zacks Investment Research cut Intellipharmaceutics International from a “hold” rating to a “sell” rating in a report on Thursday. Maxim Group set a $6.00 price objective on Intellipharmaceutics International and gave the stock a “buy” rating in a report on Saturday.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) traded down 5.0734% during mid-day trading on Monday, reaching $2.7149. The company had a trading volume of 269,212 shares. The stock’s market capitalization is $78.05 million. Intellipharmaceutics International has a 1-year low of $1.41 and a 1-year high of $3.33. The firm has a 50-day moving average price of $2.09 and a 200-day moving average price of $1.87.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/intellipharmaceutics-international-inc-ipci-given-a-8-00-price-target-at-brean-capital-2.html
Intellipharmaceutics International (NASDAQ:IPCI) last issued its quarterly earnings data on Friday, October 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.07). Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 371.11%. Equities analysts expect that Intellipharmaceutics International will post ($0.28) earnings per share for the current year.
A hedge fund recently bought a new stake in Intellipharmaceutics International stock. Atria Investments LLC acquired a new stake in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned about 0.27% of Intellipharmaceutics International as of its most recent SEC filing. Institutional investors own 1.34% of the company’s stock.
About Intellipharmaceutics International
IntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.